Pfizer Inc. (PFE) Price Target Raised

Analysts at Morgan Stanley

have raised the price target for Pfizer Inc.

from $19 to $22. The new price target for Pfizer Inc. is based on a multiple of 9x the 2011 EPS estimate $2.40. Analysts expect the management at Pfizer to lower the 2012 revenue target of $70 billion. Analysts estimate the sales to be $59 billion in 2012 but expect management to forecast a higher amount which would include future acquisitions. Analysts also expect the management to lower the 2012 EPS target of $2.42. Analysts forecast EPS of $2.10 for 2012 below the consensus EPS forecast of $2.20. Analysts expect the company to return to growth after 2012. Analysts at Morgan Stanley have an Overweight rating for Pfizer Inc.